Kleiner Perkins

$3.5B in new early- and growth-stage funds accompanied a 2026 run of Kleiner Perkins-led AI, defense and enterprise-software financings.

Who they are

Kleiner Perkins appears in the coverage as a venture firm and lead investor, spanning early-stage and later-stage rounds. Recent stories place it behind financings for AI infrastructure and applications, defense technology, healthcare and crypto data companies, while earlier coverage also tied the firm to the Ellen Pao discrimination case and portfolio-company outcomes such as Slack’s market debut.

The recent arc

Coverage reached its recent quarterly high in both 2026 Q1 and Q2, shifting decisively toward a concentrated investment and fund-deployment story. Bloomberg reported on March 24 that Kleiner Perkins raised $3.5B for a 22nd early-stage fund and a growth-stage fund; days later, CNBC reported that it led Saronic’s $1.75B Series D for autonomous military ships.

The subsequent deals reinforce a broad AI thesis rather than a single-company narrative: Kleiner Perkins led Rogo’s $160M Series D, Sail’s $80M seed and Series A for AI-model optimization software, and CuspAI’s $450M Series B alongside NEA. It also participated with Andreessen Horowitz in Mirendil’s $200M seed round and with CRV in Lotus Health’s Series A, while joining Amplify Partners in Allium’s crypto-analytics financing.

The tension

The coverage circles the pressure for an established venture platform to convert a newly enlarged capital base into leadership positions in the AI cycle, while sharing prominent rounds with rivals and co-investors including NEA, Andreessen Horowitz, CRV, Khosla Ventures and Amplify Partners. That investment-focused identity contrasts with the firm’s older, high-impact coverage, which was dominated by Ellen Pao’s gender-discrimination lawsuit and later reports of internal friction around early- versus late-stage investing.

Why it matters

If this trajectory holds, Kleiner Perkins’ significance in coverage will increasingly rest on whether its combined early- and growth-stage capacity lets it remain relevant from nascent AI companies through large late-stage rounds such as Saronic and Rogo. The current set of investments reaches from compute efficiency and developer tools to health, industrial materials and defense, but the corpus does not yet establish which of those bets will become durable category leaders.

Related: AI · Ellen Pao · Kleiner Perkins Caufield & Byers · UK-based CuspAI, which uses AI to cut rare metal use in chipmaking, ra